FDA U.S. FOOD & DRUG ADMINISTRATION

W. Drew Gill¹, Andrew N. Shen¹, Charles Law¹, Susan Burks¹, Bonnie Robinson¹, Edward Fisher², Dan Mellon², and Timothy Flanigan¹

Introduction

- CBD is a compound found in cannabis.
- Epidiolex is the only FDA-approved use of CBD and is used to treat rare childhood seizure conditions.
- There is a large market of unregulated CBD-containing products, which is estimated to reach approximately \$20 billion in sales by the year 2025.
- These CBD products are commonly used by the general public to purportedly treat inflammation, pain, and anxiety; which are also all negative symptoms of pregnancy.
- CBD is often marketed as a "safe, naturally occurring" compound, thus there is a significant likelihood of CBD use during pregnancy; however, there is currently inadequate research into its safety and efficacy.
- Cannabis use during pregnancy is linked to poor birth and developmental outcomes, and CBD cannot currently be excluded as a potential contributing factor to these effects.
- This project aims to provide a comprehensive data set to characterize neurobehavioral and neurochemical effects of perinatal CBD exposure using Sprague-Dawley rats.


Methods


- Sprague-Dawley rat dams were orally dosed via gavage once daily with CBD from gestational day (GD) 6 until the day prior to parturition.
- CBD doses include 15, 30, 100, 250, 300, and 350 mg/kg, as well as vehicle control.
- Pups were orally dosed via gavage from postnatal day (PND) 1 until PND 21 with the same dose as the respective dam.
- Brain tissue and plasma were collected at PND 21 and PND 180 for protein and neurochemistry assays.
- Pups were weaned at PND 21 for behavioral testing from PND 22 PND 180.
- CBD doses for behavior and hormone assays were 15-250 mg/kg. Pup weight, HPLC, and Western blots included a small subset of 300 mg/kg.
- Behavioral tests include tests of motor function, anxiety-like behavior, sensation and perception, and cognitive functions.

Maternal Toxicity at 350 mg/kg

Seven of 7 (100%) underwent unscheduled sacrifice due to excessive weight loss by GD 8. Pathological examination revealed all dams were gravid with non-viable fetuses. Therefore, this dose was discontinued.

Maternal and Fetal Toxicity at 300 mg/kg Offspring at Birth Subject Outcome Dam killed all pups by PND 1 13 live Necropsy showed non-viable fetuses at GD 19 10 live and 3 dead Pups failed to thrive by PND 2 Dam killed 5 of 8 pups by PND 6) live; culled to 8 11 live and 3 dead; culled to 8 Pups survived to weaning





www.fda.gov


Assessing the Developmental Neurotoxicity of Perinatal Exposure to Cannabidiol in Sprague Dawley Rats

Five of 10 dams lost offspring and/or met criteria for humane endpoint.

Average pup weights are displayed for male and female rats from PND 1–

Due to maternal and fetal toxicity, the 300 mg/kg group was not maintained after PND 21.

 $N \ge 20$ litters for all groups, except 300 mg/kg



Prepulse Intensity

68 dB 78 dB 82 dB Prepulse Intensity

collected from **CBD** treated PND 21 rats, and CBD and metabolites

												-		-		•	
	Н	orm	one	Par	nel (ng/m	nI)		Do	pami	ne a	and	Met	tabo	lites	(ng	J/g)
		Est			tradiol									Dopamine			
			Males			Females				-		Males			Females		
	Treatment	Mean	SD	Ν	Mean	SD	Ν	_		Treatment	Mean	SD	N	Mean	SD	N	
	0	0.051	0.029	8	0.050	0.022	7			0	1926.5	141.8	7	1966.9	267.6	5	
	15	0.060	0.022	5	0.044	0.013	7			15	1721.7	547.6	7	1839.6	199.4	5	
	30	0.068	0.010	4	0.037	0.034	7			30	1943.8	152.2	5	1887.7	123.8	6	
	100	0.045	0.017	4	0.050	0.021	5			100	1551.0	635.9	6	1714.1	448.4	6	
	250	0.043	0.020	7	0.050	0.010	3			250	1663.4	649.2	5	1738.2	362.1	6	
	-			Proge	sterone			-		300	2013.6	62.7	4	1850.9	62.8	3	
			Males	N I	N 4	Females	N I			-		•	hydroxyp	henylaceti			
	Treatment	Mean	SD	<u>N</u>	Mean	SD	N 7			-		Males			Females		
	0	0.051	0.029	8	0.050	0.022	7 7			Treatment	Mean	SD	Ν	Mean	SD	N	
	15	0.060	0.022	5	0.044	0.013	7 7			0	1081.2	258.4	7	942.0	286.5	5	
	30 100	0.068 0.045	0.010 0.017	4 4	0.037	0.034 0.021	7 5			15	918.9	369.2	7	927.9	180.5	5	
	250	0.045	0.017	4 7	0.050	0.021	3			30	1060.2	419.6	5	886.6	223.8	6	
	230	0.043	0.020		sterone	0.010	5	-		100 250	877.9 806.4	324.1 337.7	6 5	902.1 851.2	290.2 163.1	6 6	
	-		Males	163103	Sterone	Females				300	777.0	142.7	5 4	1223.6	138.2	3	
	Treatment	Mean	SD	N	Mean	SD	N	-		000	111.0	1.12.7		nillic Acid	100.2	Ū	
	0	0.93	0.46	8	0.70	0.35	7			-			пошоча				
	15	1.15	0.65	7	0.74	0.34	7			-		Males			Females		
	30	1.05	0.57	8	0.61	0.31	7			Treatment	Mean	SD	N	Mean	SD	N	
	100	1.15	0.64	8	0.55	0.20	7			0	977.1	173.0	7	866.3	136.5	5	
	250	1.42	0.58	8	0.62	0.23	8			15	899.3	286.3	7	885.4	165.0	5	
										30	892.9	161.3	5	828.2	98.2	6	
\ h	ormone	multip	lex kit v	was ru	n. This	assav u	ıtilized			100 250	904.9 749.3	268.7 179.6	6 5	905.6 880.1	280.2 118.3	6 6	
	plasma a	-				-				300	793.2	52.3	4	838.4	10.6	3	
	-			-		•		nale	ЦОІ								
		include decreased progesterone in the m group compared to controls															
50 mg/kg group compared to controls. were performed on PND 21 striatal tissue.																	
	Striatal TH & DAT																
_	Tyrosine hydroxylase								pamine	e Trans	sporter						
	i yrosine nyuroxyiase											•					
1.6 _–																	
								emale						Female			
		1.4 - O 1.2 -			Т			ale +	1.4 - 1.2 - 1.0 - 1.0 - 0.8 - 0.8 - 0.6 - 0.4 -	T				Male			
		0 0 1.2 -		T _	h l	Τ	1	Ć) 1.2 -	Т	т	ΤT	_ T	тΤ			
		ale	ΤI		T I .	- T 	T				L II	. .					
		- 0.1 Eemale				<u>,</u> , , , , , , , , , , , , , , , , , ,			1.0 -								
								Ĺ	0.8 -								
		Change to - 9.0						+									
		0.6 -							0.6 -								
		e 0.4 -							0.4 -								
		0 g						ך בי									
		PIO 0.2 -							0.2 -								
									- 0.0						_		
		0.0	0 mg/kg	15mg/kg	30 mg/kg 10	00 mg/kg 250 mg	/kg_300 mg/	kg		0 mg/kg 15mg	ı/kg 30 mg/k	kg 100 mg/k	g 250 mg/kg	300 mg/kg			

Motor coordination was assayed via accelerating Rotarod at PND 27,


rod is displayed on the y-axis, with

Anxiety-like behavior was assayed via elevated-plus maze on PND 41.

Average percent time spent in the displayed. More time in open arms is indicative of lower anxiety-like

Startle response and sensory motor gating were measured via PPI on PND measured in mV to a 120 dB stimuli

Average percent PPI is shown in the bottom panels to 3 distinct prepulse levels displayed on the y-axis, with the prepulse dB levels on the x-axis.



Average fold change relative to female controls for striatal TH and DAT are shown on the left and right, respectively. Striatal tissue was isolated from PND 21 rat brains for 6 CBD treatment groups. Relative protein amount was measured via Western blot and normalized to beta-actin. Representative blots are displayed below each graph and show bands (red = beta-actin) for all 6 treatment groups in order from Vehicle control (1) to 300 mg/kg (6). $N \ge 7$ for all groups.

Maternal toxicity was observed at 350 mg/kg.

- pre-weaning pups (PND 19-21).

- proteins, TH and DAT, in the striatum.

This study was supported by FDA/NCTR protocol E07731 with funding from US FDA Office of the Chief Scientist (CS-challenge) intramural grant. Additional funding was provided by the Center for Food Safety and Applied Nutrition (CFSAN/FDA) and the Center for Drug Evaluation and Research (CDER/FDA). WDG was supported by a postdoctoral fellowship from ORISE. We are grateful to the many individuals who have contributed to this project.

Disclaimer: The information in these materials is not a formal dissemination of information by FDA and does not represent agency position or policy. These data are unpublished and in progress and are not to be cited.

¹National Center for Toxicological Research, Jefferson, AR 72079 ²Center for Drug Evaluation and Research, Silver Springs, MD 20903

g/kg 100 mg/kg 250 mg	g/kg_300 mg/kg	0 mg/k	kg 15mg/kg 30 m	ig/kg 100 mg/kg 250 mg	/kg 300 mg/kg
Female	Male	Female	Male	Female	Male
Dose 5 1 2 3 4 5 6	Dose 1 2 3 4 5 6	Dose 1 2 3 4 5 6	Dose 1 2 3 4 5 6	Dose 5 1 2 3 4 5 6	Dose 1 2 3 4 5 6
	ہے ہے ہے جے ک				

Conclusions

Maternal and fetal toxicity was observed at 300 mg/kg.

Preliminary analysis suggests that very high dose CBD, 300 mg/kg, reduced body weight in

Preliminary behavior analyses suggest CBD did not have dose-dependent effects on motor function, anxiety-like behavior, cognition, or memory.

CBD did not have an effect on plasma levels of developmental hormones, except the highest dose, 250 mg/kg, reduced progesterone in male rats.

CBD did not affect levels of dopamine, dopamine metabolites, or dopamine-related

Standard brain histopathology and immunohistochemistry are in progress.

Acknowledgments